Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Immune privilege or inflammation? Insights into the Fas ligand enigma

Nature Medicine volume 7, pages 271–274 (2001)Cite this article

Abstract

Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Inflammatory effects of FasL.

References

  1. Restifo, N.P. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nature Med. 6, 493–495 (2000).

    Article  CAS  Google Scholar 

  2. Griffith, T.S. & Ferguson, T.A. The role of FasL-induced apoptosis in immune privilege. Immunol. Today 18, 240–244 (1997).

    Article  CAS  Google Scholar 

  3. Lepple-Wienhues, A. et al. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc. Natl. Acad. Sci. USA 96, 13795–13800 (1999).

    Article  CAS  Google Scholar 

  4. Sampalo, A. et al. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 96, 3168–3174 (2000).

    CAS  PubMed  Google Scholar 

  5. Kang, S.-M. et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738–743 (1997).

    Article  CAS  Google Scholar 

  6. O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20, 46–52 (1999).

    Article  CAS  Google Scholar 

  7. O'Connell, J. et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186, 240–246 (1998).

    Article  CAS  Google Scholar 

  8. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K.J. & Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94, 6420–6425 (1997).

    Article  CAS  Google Scholar 

  9. Yoong, K.F., Afford, S.C., Randhawa, S., Hubscher, S.G. & Adams, D.H. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 154, 693–703 (1999).

    Article  CAS  Google Scholar 

  10. Mann, B. et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br. J. Cancer 79, 1262–1269 (1999).

    Article  CAS  Google Scholar 

  11. Peduto Eberl, L. et al. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int. J. Cancer 81, 772–778. (1999).

    Article  CAS  Google Scholar 

  12. Arbuckle, E., Langlois, N.E.I., Eremin, O. & Heys, S.D. Evidence for Fas counterattack in vivo from a study of colorectal cancer. Oncol. Rep. 7, 45–47 (2000).

    CAS  PubMed  Google Scholar 

  13. Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res. 6, 3560–3564 (2000).

    CAS  PubMed  Google Scholar 

  14. Papoff, G. et al. Technical comment: constitutive expression of FasL in thyrocytes; reply. Science 279, 2015a (1998).

    Article  Google Scholar 

  15. Sikora, J., Dworacki, G. & Zeromski, J. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions. Nat. Immun. 16, 244–255 (1998).

    Article  CAS  Google Scholar 

  16. Zaks, T.Z., Chappell, D.B., Rosenberg, S.A. & Restifo, N.P. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162, 3273–3279 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075–1082 (1996).

    Article  CAS  Google Scholar 

  18. Bennett, M.W. & O'Connell, J. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669–5675 (1998).

    CAS  Google Scholar 

  19. Shibakita, M. et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin. Cancer Res. 5, 2464–2469 (1999).

    CAS  PubMed  Google Scholar 

  20. Munakata, S. et al. Expression of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br. J. Cancer 82, 1446–1452 (2000).

    Article  CAS  Google Scholar 

  21. Khar, A., Varalakshmi, C., Pardhasaradhi, B.V.V., Mubarak Ali, A. & Kumari, A.L. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: a mechanism of immune evasion. Cell. Immunol. 189, 85–91 (1998).

    Article  CAS  Google Scholar 

  22. Nagarkatti, N. Tumor-derived Fas ligand induces toxicity in lymphoid organs and plays an important role in successful chemotherapy. Cancer Immunol. Immunother. 49, 46–55 (2000).

    Article  CAS  Google Scholar 

  23. Reimer, T. et al. FasL:Fas ratio—a prognostic factor in breast carcinomas. Cancer Res. 60, 822–828 (2000).

    CAS  PubMed  Google Scholar 

  24. Mottolese, M. et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int. J. Cancer 89, 127–132 (2000).

    Article  CAS  Google Scholar 

  25. Ito, Y. et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br. J. Cancer 82, 1211–1217 (2000).

    Article  CAS  Google Scholar 

  26. Kim, Y.-S. et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch. Pathol. Lab. Med. 124, 687–693 (2000).

    CAS  PubMed  Google Scholar 

  27. Volm, M. & Koomagi, R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br. J. Cancer 82, 1747–1754 (2000).

    Article  CAS  Google Scholar 

  28. Mor, G. et al. Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J. Steroid Biochem. Mol. Biol. 73, 185–194 (2000).

    Article  CAS  Google Scholar 

  29. Yakes, F.M. et al. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. Cancer Res. 60, 5740–5746 (2000).

    CAS  PubMed  Google Scholar 

  30. Li, X.K. et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 66, 1416–1423 (1998).

    Article  CAS  Google Scholar 

  31. Swenson, K.M. et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65, 155–160 (1998).

    Article  CAS  Google Scholar 

  32. Hohlbaum, A.M., Moe, S. & Marshak-Rothstein, A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 191, 1209–1219 (2000).

    Article  CAS  Google Scholar 

  33. Schaub, F.J. et al. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nature Med. 6, 790–796. (2000).

    Article  CAS  Google Scholar 

  34. Jarry, A. et al. Interleukin 1 and interleukin 1β converting enzyme (caspase-1) expression in the human colonic epithelial barrier. Caspase-1 downregulation in colon cancer. Gut 45, 246–251 (1999).

    Article  CAS  Google Scholar 

  35. Moller, P. et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57, 371–377 (1994).

    Article  CAS  Google Scholar 

  36. Chen, J.-J., Sun, Y. & Nabel, G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714–1717 (1998).

    Article  CAS  Google Scholar 

  37. Streilein, J.W. Unraveling immune privilege. Science 270, 1158–1159 (1995).

    Article  CAS  Google Scholar 

  38. Kelly, L., Reid, L. & Walker, N.I. Massive acinar cell apoptosis with secondary necrosis, origin of ducts in atrophic lobules and failure to regenerate in cyanohydroxybutene pancreatopathy in rats. Int. J. Exp. Pathol. 80, 217–226 (1999).

    Article  CAS  Google Scholar 

  39. Matsue, H. et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nature Med. 5, 930–937 (1999).

    Article  CAS  Google Scholar 

  40. Waku, T. et al. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer. J. Immunol. 165, 5884–5890 (2000).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the Health Research Board of Ireland and the Wellcome Trust for research funding.

Author information

Authors and Affiliations

  1. Department of Medicine, University Hospital, National University of Ireland, Cork, Ireland

    Joe O'Connell, Aileen Houston, Michael W. Bennett & Fergus Shanahan

  2. Department of Surgery, Mercy Hospital, National University of Ireland, Cork, Ireland

    Gerald C. O'Sullivan

Authors
  1. Joe O'Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aileen Houston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael W. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerald C. O'Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fergus Shanahan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Connell, J., Houston, A., Bennett, M. et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7, 271–274 (2001). https://doi.org/10.1038/85395

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/85395

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing